Hormonal
SGLT2 inhibitors are preferred over GLP1RAs for adults with type 2 diabetes and heart failure to reduce major adverse cardiovascular events and worsening heart failure, while GLP1RAs are preferred for chronic kidney disease if SGLT2is are not tolerated.
If you have type 2 diabetes and heart failure, ask about SGLT2 inhibitors (like empagliflozin or dapagliflozin), as they are proven to help your heart. If you have kidney disease, SGLT2 inhibitors are also preferred, but if you can't take them, GLP-1 agonists (like dulaglutide) are a good alternative for protecting your kidneys. Your doctor will choose based on your specific organ risks.
Accordingly, in people with heart failure, an SGLT2i with known benefit should be started to reduce the risk of major adverse cardiovascular events and worsening heart failure. If SGLT2is are not tolerated or cannot be used, GLP1RAs with demonstrated renal benefit are a reasonable alternative.
Why this rating
Based on dedicated kidney outcome trials and consistent CVOT data for heart failure.
Source
Advances in the management of type 2 diabetes in adults
Rodolfo J. Galindo et al. · BMJ Medicine · 2023
DOI 10.1136/bmjmed-2022-000372
More from this paper
- For adults with type 2 diabetes and established atherosclerotic cardiovascular disease or high risk, glucagon-like peptide 1 receptor agonists (GLP1RAs) or sodium glucose cotransporter 2 inhibitors (SGLT2is) should be initiated as first-line therapy regardless of baseline HbA1c levels to reduce major adverse cardiovascular events.Strong
- Intensive lifestyle interventions (diet and exercise) alone do not significantly reduce cardiovascular event risk in overweight/obese adults with type 2 diabetes compared to usual care, whereas weight loss achieved through metabolic surgery significantly reduces complications and mortality.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →